Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated plasmodium falciparum malaria: A comparative, multicenter, randomized clinical trial

• Main Authors: Neena Valecha, Srivicha Krudsood, Noppadon Tangpukdee, Sanjib Mohanty, S. K. Sharma, P. K. Tyagi, Anupkumar Anvikar, Rajesh Mohanty, B. S. Rao, A. C. Jha, B. Shahi, Jai Prakash Narayan Singh, Arjun Roy, Pawandeep Kaur, Monica Kothari, Shantanu Mehta, Anirudh Gautam, Jyoti K. Paliwal, Sudershan Arora, Nilanjan Saha
• Other Authors: National Institute of Malaria Research India
• Format: Article
• Published: 2018
• Subjects: Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/14673
• Institution: Mahidol University

Background.Artemisinin-based combination therapy is the first-line treatment for uncomplicated falciparum malaria. This study assessed the antimalarial efficacy and safety of a combination of 150 mg of arterolane maleate and 750 mg of piperaquine phosphate (AM-PQP) in comparison to Coartem (artemether and lumefantrine) in patients with acute uncomplicated P. falciparum malaria.Methods.In this open-label, randomized, multicentric, parallel group clinical trial, 240 patients were randomized to receive AM-PQP (160 patients) or Coartem (80 patients). Patients with P. falciparum monoinfection and initial parasite densities ranging from 1000 to 100 000 asexual parasites/L of blood were followed for 28 days. Polymerase chain reaction-corrected adequate clinical and parasitologic response on day 28, parasite clearance time, and fever clearance time were evaluated.Results.A total of 151 (94.4) of 160 patients in the AM-PQP group completed the trial, while 77 (96.3) of 80 patients in the Coartem group completed the trial. No treatment failure was noted in the AM-PQP group, while one patient receiving Coartem failed treatment on day 28. There was no difference in the median parasite clearance time (30 hours in both groups) or median fever clearance time (24 hours in both groups) after administration of the 2 study treatments.Conclusions.The available data support the evaluation of a drug combination in a larger population as a fixed-dose combination.Clinical Trials Registration.CTRI/2007/091/000031. © The Author 2012.